Home
Biomarkers Summit
16 January - 17 January 2013
Biomarkers Summit

SAE Media Group’s sixth Annual Biomarkers conference unites advances in biomarker use for drug discovery and development, alongside biomarkers for cancer.  This two-day meeting showcases the best new opportunities and strategies to accelerate go/no-go decision making in early and clinical development.

Key academic, government and industry figures cover topics encompassing:

  • Case studies in idiopathic pulmonary fibrosis (IPF) and molecular characterisation of solid tumors
  • Interactive panel discussion focusing on current developments in personalised medicine via biomarkers
  • Latest advancements in molecular diagnostics and multi-centre clinical imaging studies
  • New developments in pharmacogenetic and pharmacogenomic statistical study design
  • Future direction and initiatives for safety biomarkers
  • Maximise the cost-effectiveness of your companion diagnostic for end-users

FEATURED SPEAKERS

Andrew Warren

Andrew Warren

Director, PK/PD/Immunogenicity Bioanalysis, Novartis Pharma
Graham Bell

Graham Bell

Lead Technologist, Stratified Medicine, Technology Strategy Board
Nicholas Buss

Nicholas Buss

Toxicology Project Leader, MedImmune
Nick  Crabb

Nick Crabb

Associate Director - Diagnostics Assessment Programme, National Institute for Health and Clinical Excellence

Aiden Flynn

Managing Director, Exploristics
Aiden Flynn

Andrew Warren

Director, PK/PD/Immunogenicity Bioanalysis, Novartis Pharma
Andrew Warren

Balazs Sarkadi

Head, Membrane Biology Research Group, Hungarian Academy of Sciences
Balazs Sarkadi

Graham Bell

Lead Technologist, Stratified Medicine, Technology Strategy Board
Graham Bell

Jill Walker

Diagnostics Director, AstraZeneca
Jill Walker

Lisa Thompson

Laboratory Manager and Clinical Scientist, The Royal Marsden NHS Foundation Trust
Lisa Thompson

Mark Caulfield

Director of Institute, The William Harvey Research Institute, Barts and The London School of Medicine & Dentistry
Mark Caulfield

Mark Fidock

Group Director, Biomarkers & Translational Sciences, Strategic Development, Huntingdon Life Sciences
Mark Fidock

Matthew Baker

Chief Scientific Officer, Antitope
Matthew Baker

Nicholas Buss

Toxicology Project Leader, MedImmune
Nicholas Buss

Nick Crabb

Associate Director - Diagnostics Assessment Programme, National Institute for Health and Clinical Excellence
Nick  Crabb

Peter Parker

Deputy Director of the Integrated Cancer Centre and Head of the Division of Cancer Studies , Kings College
Peter Parker

Simon Walker-Samuel

Senior Research Associate, Centre for Advanced Biomedical Imaging, UCL
Simon Walker-Samuel

Veronique Bragulat

Clinical Imaging Manager, GSK
Veronique Bragulat

Yasmina Bauer

Senior Lab Head, Translational Science Biology, Actelion Pharmaceuticals
Yasmina Bauer

Yi Yang

Research Investigator, Abbott Laboratories
Yi Yang

Yu Shyr

Director of the Vanderbilt Center for Quantitative Sciences, Vanderbilt University Medical Center
Yu Shyr

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Nicholas Buss

Nicholas Buss, Toxicology Project Leader, MedImmune

clock

9:10

Biomarkers: discovery strategies and technologies

Peter Parker

Peter Parker, Deputy Director of the Integrated Cancer Centre and Head of the Division of Cancer Studies , Kings College

  • Strategies for providing truly personalised predictive biomarkers and drugs in use and in development
  • Review of some emerging new technologies for generating sophisticated readouts directly informative on drug action
  • Predictions of drug responsiveness
  • clock

    9:45

    Pharmacogenomic biomarkers- an update

    Mark Caulfield

    Mark Caulfield, Director of Institute, The William Harvey Research Institute, Barts and The London School of Medicine & Dentistry

  • Progress in identifying gene regions coding for drug targets
  • Results from genome-wide association studies
  • Meeting the technical challenges of stratified medicine and companion diagnostics
  • clock

    10:20

    How to do it: pharmacogenetics and biomarkers - clinical study and statistical design

    Aiden Flynn

    Aiden Flynn, Managing Director, Exploristics

  • Design considerations
  • Association analysis
  • Design options
  • Case studies and applications
  • clock

    10:55

    Morning Coffee

    clock

    11:25

    CASE STUDY: Translational value of the bleomycin rat model for the treatment of patients with idiopathic pulmonary fibrosis (IPF)

    Yasmina Bauer

    Yasmina Bauer, Senior Lab Head, Translational Science Biology, Actelion Pharmaceuticals

  • Whole-genome data collected from an IPF animal model time-course experiment
  • Comparison of animal model data from IPF patient-derived lung biopsies
  • New possibilities to evaluate efficacy of novel therapeutics in preclinical models and human clinical trials
  • clock

    12:00

    Translational biomarkers in drug development

    Mark Fidock

    Mark Fidock, Group Director, Biomarkers & Translational Sciences, Strategic Development, Huntingdon Life Sciences

  • Challenges and risk management in the development of new medicines
  • Strategic development and use of biomarkers in translational medicine
  • Case study: the TLR7 drug development programme
  • clock

    12:35

    Renal safety biomarkers

    Yi Yang

    Yi Yang, Research Investigator, Abbott Laboratories

  • Overview challenges and opportunities
  • Urinary biomarker qualification efforts
  • Current regulatory status
  • Validation and implementation of urinary biomarkers
  • clock

    13:10

    Networking Lunch

    clock

    14:10

    On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models

    Andrew Warren

    Andrew Warren, Director, PK/PD/Immunogenicity Bioanalysis, Novartis Pharma

  • Delivering safe starting and therapeutically relevant escalation doses for human studies
  • Target-mediated drug disposition
  • Assaying captured drug-target complexes
  • clock

    14:45

    Safety biomarkers for risk assessment of investigative drugs entering first-in-human studies

    Nicholas Buss

    Nicholas Buss, Toxicology Project Leader, MedImmune

  • The principles of biomarkers for both safety and efficacy in regulatory toxicology studies
  • Classical and emerging biomarkers used in regulatory toxicology studies to support FIH studies.
  • Future direction and initiatives for safety biomarkers
  • clock

    15:20

    Afternoon Tea

    clock

    15:50

    Understanding the mechanisms involved in immune responses to therapeutic proteins

    Matthew Baker

    Matthew Baker, Chief Scientific Officer, Antitope

  • Development of immune responses directed against protein therapeutics
  • Antigen presentation and T-dependent responses
  • Models for predicting immunogenicity
  • Reducing immunogenicity by design
  • clock

    16:25

    Panel discussion: Personalised medicine via biomarkers- where are we and what are the prospects for the future?

    Topics discussed will include recent advances in multiple omics technologies with the help of bioinformatics and biostatistics to improve the discovery and development of robust biomarkers for complex chronic diseases. Developing a consistent framework for the validation, acceptance and qualification of biomarkers for regulatory use and clinical phases of drug development will also be discussed.  The panel will comprise a selection of the day’s speakers.

    Aiden Flynn

    Aiden Flynn, Managing Director, Exploristics

    Yasmina Bauer

    Yasmina Bauer, Senior Lab Head, Translational Science Biology, Actelion Pharmaceuticals

    Yi Yang

    Yi Yang, Research Investigator, Abbott Laboratories

    Balazs Sarkadi

    Balazs Sarkadi, Head, Membrane Biology Research Group, Hungarian Academy of Sciences

    clock

    17:00

    Chairman’s Closing Remarks and Close of Day One

    Andrew Warren

    Andrew Warren, Director, PK/PD/Immunogenicity Bioanalysis, Novartis Pharma

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Jill Walker

    Jill Walker, Diagnostics Director, AstraZeneca

    clock

    9:10

    The challenges of translating biomarkers into clinical diagnostics

    Jill Walker

    Jill Walker, Diagnostics Director, AstraZeneca

  • Identifying patient subpopulations with improved response
  • Adapting development strategies to deliver companion diagnostics
  • Ensuring access to diagnostics
  •  

    clock

    9:50

    Membrane proteins as personalised biomarkers

    Balazs Sarkadi

    Balazs Sarkadi, Head, Membrane Biology Research Group, Hungarian Academy of Sciences

    clock

    10:30

    Morning Coffee

    clock

    11:00

    Novel clinical trial design in the era of high-density biomarker data

    Yu Shyr

    Yu Shyr, Director of the Vanderbilt Center for Quantitative Sciences, Vanderbilt University Medical Center

  • Understanding high-density biomarker data
  • Repeatability and reproducibility of the pre-clinical high-density biomarker data
  • Intra & inter-tumor/subject variability
  • Pathway of drug development based on high-density biomarker data
  • clock

    11:40

    Opportunities for the development of stratified medicine in the UK

    Graham Bell

    Graham Bell, Lead Technologist, Stratified Medicine, Technology Strategy Board

  • Description of the Technology Strategy Board’s Stratified Medicine Innovation Platform
  • Joining up academia, diagnostic and therapeutic development and driving product uptake
  • Encouraging wide collaboration from biomarker discovery to product launch
  • Current and future focus for public funding
  • clock

    12:20

    Networking Lunch

    clock

    13:40

    Evaluating the cost-effectiveness of diagnostics: the NICE diagnostics assessment programme

    Nick  Crabb

    Nick Crabb , Associate Director - Diagnostics Assessment Programme, National Institute for Health and Clinical Excellence

  • Explaining the structure and purpose of the diagnostics assessment programme
  • Evaluating the cost-effectiveness of a diagnostic test
  • Explaining how the diagnostics industry can engage with the programme
  • clock

    14:20

    CASE STUDY: Molecular characterisation of solid tumours to aid stratified medicine

    Lisa Thompson

    Lisa Thompson, Laboratory Manager and Clinical Scientist, The Royal Marsden NHS Foundation Trust

  • Improving diagnostic strategies to facilitate personalised therapeutic interventions
  • BRAF V600 mutation testing for malignant melanoma
  • KRAS mutation testing for patients with colorectal cancer
  • clock

    15:00

    Afternoon Tea

    clock

    15:30

    Multi-centre imaging in the context of clinical trials

    Veronique Bragulat

    Veronique Bragulat, Clinical Imaging Manager, GSK

  • Managing multi-centre clinical trials and their associated challenges in oncology
  • Examples of best practice in imaging models
  • Notable trends gleaned from such studies
  • clock

    16:10

    Imaging biomarkers of cancer progression

    Simon Walker-Samuel

    Simon Walker-Samuel, Senior Research Associate, Centre for Advanced Biomedical Imaging, UCL

  • Noninvasive Measurement of tumor blood flow and interstitial fluid pressure
  • Tumor adaptations to ensure nutrient delivery
  • Assessing metatstatic potential
  • clock

    16:50

    Chairman’s Closing Remarks and Close of Day Two


    Deputy Director of the Integrated Cancer Centre and Head of the Division of Cancer Studies
    Kings College
    Diagnostics Director
    AstraZeneca
    Head, Membrane Biology Research Group
    Hungarian Academy of Sciences
    Director of the Vanderbilt Center for Quantitative Sciences
    Vanderbilt University Medical Center
    Lead Technologist, Stratified Medicine
    Technology Strategy Board
    Associate Director - Diagnostics Assessment Programme
    National Institute for Health and Clinical Excellence
    Laboratory Manager and Clinical Scientist
    The Royal Marsden NHS Foundation Trust
    Clinical Imaging Manager
    GSK
    Senior Research Associate, Centre for Advanced Biomedical Imaging
    UCL
    Director of Institute
    The William Harvey Research Institute, Barts and The London School of Medicine & Dentistry
    Managing Director
    Exploristics
    Senior Lab Head, Translational Science Biology
    Actelion Pharmaceuticals
    Group Director, Biomarkers & Translational Sciences, Strategic Development
    Huntingdon Life Sciences
    Research Investigator
    Abbott Laboratories
    Director, PK/PD/Immunogenicity Bioanalysis
    Novartis Pharma
    Toxicology Project Leader
    MedImmune
    Chief Scientific Officer
    Antitope

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.